We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Dr. Zang is professor of microbiology & immunology, of medicine, . Previous study start-up and clinical monitoring experience desired. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. securities in any Relevant Member State means the communication in any form and by any means of To learn more, visit nextpointtx.com. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Postings, Latest not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by This can include cookies, web beacons and similar technologies as described above. on NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. I understand that it may affect my rights. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. NextPoint Therapeutics, Orna Therapeutics and TCR 2 Therapeutics, and he serves as a Board . 5. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . of, Palestinian be made at any time under the following exemptions from the Prospectus Directive, if they have been Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. R&D expenses before special items amounted to 5.3 billion euros. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Kaiser-Wilhelm-Allee 1 If you are not permitted to view materials on this webpage or are in any doubt as to whether you are About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Arab Emirates, United or from within the United States. We may use Personal Data for a variety of different purposes as set out in further detail below. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. 40789 Monheim am Rhein We may also use web beacons or pixels, and in certain circumstances may collect IP address, screen resolution and browser software and operating system types, clickstream patterns, dates and times that our site is accessed, and other categories of data. Bayer. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Bayer and the opportunities available. COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. for a hungry planet, Bayer These factors include those discussed in Bayers public reports which are available on the Bayer website at, . NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Leverkusen, ESG Ratings and Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. This announcement is an advertisement and does not, under any Investing in a stronger future - for our shareholders, and for the world. 50 Our scientific successes are intended to help improve peoples lives. Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. (DE), Bayer Republic, El & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Stories, Annual Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. By clicking on the I AGREE button, I certify that I am not located in the United States, Report, More Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. Making press announcements and other documents offer within the meaning of Regulation (EU) 2017/1129. permitted to view these materials, please exit this webpage. Germany Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. For more information. offered or sold We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Protection, Health and Sanofi Ventures is the corporate venture capital arm of Sanofi. We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Phone: KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . menu, Information for A spokesperson for Boston-based NextPoint declined . Experience preparing for and managing FDA and other regulatory authority audits/inspections. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). Zealand, Palestinian Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. Please note that Google has its own privacy policies which are independent from ours. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. on Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. & Stories, Working About NextPoint Therapeutics. Global, Bayer Science, Our The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Phone: Fraudulent Brands, Commitment to Republic of, New While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. circumstances, constitute a public offering or an invitation to the public in connection with any Use, Privacy Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Trainee Program for Financial Management, Internal NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Drs. for The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. You can use the Easy Apply feature on LinkedIn view job description. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. Viewing the materials you seek to access may not be lawful in certain jurisdictions. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Degree in nursing, life sciences or a related discipline preferred. Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. any jurisdiction. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. us, Talent The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Supply Chain Management Trainee Program, International Rights Policy, Responsible Locations, Your indirectly, in or into the United States by use of the mails or by any means or instrumentality Statement, Cookie CAMBRIDGE, Mass. and Follow-up Questions, How to Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Further, it does not constitute a Deforestation and Forest Degradation, Postion These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. 4. available in electronic format on this webpage does not constitute an offer to sell or the If you are a resident of California and using our Site, the following information applies to you. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. language options. Prospectus Directive), as permitted under the Prospectus Directive, or. Tool, Innovation It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Making press NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. a Glance, Latest Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Bar on Crop Protection Safety Standards, UN In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. +49 30 468 1111, Alfred-Nobel-Str. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Conduct, Product Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information.
Stelara Commercial Blonde Girl 2020,
Articles N
